Which medications can cause elevated troponin levels?

Medications That Can Cause Elevated Troponin

Cardiotoxic chemotherapy agents—particularly anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), 5-fluorouracil, trastuzumab, and immune checkpoint inhibitors (nivolumab)—are the primary medications that cause troponin elevation through direct myocardial injury. 1, 2, 3

Chemotherapeutic Agents

Anthracyclines (Type I Cardiotoxicity)

Anthracyclines cause irreversible myocardial damage with troponin elevation occurring in 30-50% of patients shortly after drug administration. 1

• Doxorubicin elevates cardiac troponin I (cTnI) in 32% of patients receiving high-dose therapy, with increases occurring in more than 50% of patients soon after administration 1
• Epirubicin, daunorubicin, and idarubicin produce similar cardiotoxic effects with troponin release proportional to cumulative dose 2
• Troponin elevation after anthracyclines predicts subsequent left ventricular dysfunction and major adverse cardiac events within the first year 1
• In children treated with high-dose doxorubicin for acute lymphoblastic leukemia, cardiac troponin T (cTnT) increases in approximately 30% of cases, with the magnitude predicting cardiac dysfunction during follow-up 1
• Persistent troponin elevation (not transient) after anthracycline therapy is associated with higher probability of major cardiac events 1

Targeted Therapy Agents (Type II Cardiotoxicity)

Trastuzumab causes reversible myocardial injury with troponin elevation, particularly in patients previously exposed to anthracyclines. 1, 2

• High-sensitivity cTnI elevation combined with a decrease in global longitudinal strain ≥19% is highly specific for predicting cancer therapy-related cardiac dysfunction in patients receiving trastuzumab 1
• Expert panels recommend measuring cTnI at baseline and every 3 weeks during trastuzumab therapy 1
• The utility of troponin for predicting trastuzumab cardiotoxicity is more helpful in patients with prior anthracycline exposure 4

Fluoropyrimidines

5-Fluorouracil (5-FU) causes cardiac ischemia and troponin elevation in 1-68% of patients, typically within 2-5 days of starting therapy. 5, 3

• Cardiac toxicity manifests as ischemic ECG changes in up to 68% of patients, though evidence of myocyte damage with troponin elevation is less consistent 5
• Coronary artery thrombosis, arteritis, and vasospasm are proposed mechanisms 5

Immune Checkpoint Inhibitors

Nivolumab and other checkpoint inhibitors can cause myocarditis with persistently elevated troponin levels that may remain elevated for months despite immunosuppression. 6

• Myocarditis from checkpoint inhibitors is rare but can result in mortality 6
• Troponin elevation may persist despite clinical remission of myocarditis and treatment with corticosteroids and mycophenolate mofetil 6

Other Chemotherapy Agents

• Bevacizumab in combination regimens has been associated with cardiac dysfunction, though the relationship between troponin elevation and EF decline is less clear 1
• Cyclophosphamide and paclitaxel in combination regimens contribute to cardiotoxicity 1

Medications Causing Indirect Troponin Elevation

Diabetic Medications

Medications that cause hypoglycemia (insulin, sulfonylureas) can lead to myocardial damage and troponin elevation through supply-demand mismatch. 7

• Severe hypoglycemia is associated with 34% higher high-sensitivity troponin T (hsTnT) levels in unadjusted analysis and 17% higher after adjustment for baseline factors 7
• Hypoglycemia occurring ≥weekly is associated with 14% higher hsTnT in unadjusted analysis 7
• The association may be due to more severe diabetes in patients who develop hypoglycemia rather than direct hypoglycemic injury 7

Clinical Monitoring Recommendations

For Anthracycline Therapy

Measure high-sensitivity troponin I at baseline and with each cycle of anthracycline-containing chemotherapy in high-risk patients. 2, 4

• Perform cardiac function assessment at baseline and after cumulative doxorubicin dose of 240 mg/m² (or equivalent) in patients with high baseline risk 2
• Reassess at the end of treatment, particularly when consecutive treatment with potentially cardiotoxic targeted therapies will follow 2
• Elevation of troponin identifies patients who may benefit from cardioprotective therapy with ACE inhibitors 5

For Trastuzumab Therapy

Measure cTnI at baseline and every 3 weeks during trastuzumab therapy, accompanied by echocardiography with global longitudinal strain at baseline and every 3 months. 1

• The combination of elevated high-sensitivity cTnI and decreased GLS ≥19% is highly specific for predicting cardiotoxicity 1

For High-Risk Patients

In patients with relapsed multiple myeloma or those receiving high-dose cardiotoxic chemotherapy, obtain baseline troponin before initiating therapy. 4

• Baseline troponin elevation identifies individuals at greatest risk for developing cardiovascular dysfunction 4
• Early rises in troponin during initial therapy are highly predictive of cardiac events 4

Key Pitfalls to Avoid

• Do not dismiss troponin elevations during chemotherapy as "false positives"—they represent genuine myocardial injury requiring evaluation 3, 8
• Timing of blood draw relative to chemotherapy administration is critical—samples drawn before chemotherapy may miss troponin release 1
• Do not rely solely on troponin—combine with echocardiography and strain imaging for optimal cardiotoxicity detection 1, 2
• Persistent troponin elevation (not transient) is the key predictor—only patients with persistent elevation develop overt heart failure 1
• Troponin elevation warrants cardiology consultation, preferably with a cardio-oncology specialist, and consideration of cardioprotective therapy with ACE inhibitors, ARBs, and/or beta-blockers 4